The involvement of hypoxia‐inducible factor‐1α in the susceptibility to γ‐rays and chemotherapeutic drugs of oral squamous cell carcinoma cells
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
The transcription factor hypoxia‐inducible factor‐1α (HIF‐1α) is the key regulator that controls the hypoxic response of mammalian cells. The overexpression of HIF‐1α has been demonstrated in many human tumors. However, the role of HIF‐1α in the therapeutic efficacy of chemotherapy and radiotherapy in cancer cells is poorly understood. In this study, we investigated the influence of HIF‐1α expression on the susceptibility of oral squamous cell carcinoma (OSCC) cells to chemotherapeutic drugs (cis‐diamminedichloroplatinum and 5‐fluorouracil) and γ‐rays. Treatment with chemotherapeutic drugs and γ‐rays enhanced the expression and nuclear translocation of HIF‐1α, and the susceptibility of OSCC cells to the drugs and γ‐rays was negatively correlated with the expression level of HIF‐1α protein. The overexpression of HIF‐1α induced OSCC cells to become more resistant to the anticancer agents, and down‐regulation of HIF‐1α expression by small interfering RNA enhanced the susceptibility of OSCC cells to them. In the HIF‐1α‐knockdown OSCC cells, the expression of P‐glycoprotein, heme oxygenase‐1, manganese‐superoxide dismutase and ceruloplasmin were downregulated and the intracellular levels of chemotherapeutic drugs and reactive oxygen species were sustained at higher levels after the treatment with the anticancer agents. These results suggest that enhanced HIF‐1α expression is related to the resistance of tumor cells to chemo‐ and radio‐therapy and that HIF‐1α is an effective therapeutic target for cancer treatment. © 2006 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998) · Nature · doi:10.1038/28867 · Cited by 2,502
Talks, K. L., Turley, H., Gatter, K. C., Maxwell, P. H., Pugh, C. W., Ratcliffe, P. J., & Harris, A. L. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64554-3 · Cited by 1,312
Lee, P. J., Jiang, B.-H., Chin, B. Y., Iyer, N. V., Alam, J., Semenza, G. L., & Choi, A. K. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.9.5375 · Cited by 782
Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1α-degradative pathway
Isaacs, J. S., Jung, Y.-J., Mimnaugh, E. G., Martinez, A., Cuttitta, F., & Neckers, L. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204733200 · Cited by 663
Erler, J. T., Cawthorne, C. J., Williams, K. J., Koritzinsky, M., Wouters, B. G., Wilson, C., Miller, C., Demonacos, C., Stratford, I. J., & Dive, C. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.7.2875-2889.2004 · Cited by 400
The hypoxia-inducible factor-1α is a negative factor for tumor therapy
Unruh, A., Ressel, A., Mohamed, H. G., Johnson, R. S., Nadrowitz, R., Richter, E., Katschinski, D. M., & Wenger, R. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206385 · Cited by 334 · cited 1×
“the facts that inhibitors of HIF-1 inhibit tumor growth and enhance the tumor sensitivity to anticancer agents.(36,37) In the present study, however, OSCC cells did not become completely susceptible to chemotherapeutic drugs and g-rays even though the expression of HIF1a was completely knocked down by HIF-1a-siRNA dup…”
BackgroundReactive oxygen species in the control of hypoxia-inducible factor-mediated gene expression
Kietzmann, T., & Görlach, A. (2005) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2005.03.010 · Cited by 295
Wartenberg, M., Ling, F. C., Müschen, M., Klein, F., Acker, H., Gassmann, M., Petrat, K., Pütz, V., Hescheler, J., & Sauer, H. (2003) · The FASEB Journal · doi:10.1096/fj.02-0358fje · Cited by 287 · cited 1×
“MDR1 gene expression with subsequent functional P-gp expression is markedly upregulated in a HIF-1-dependent manner in response to hypoxia.(18,19) Hypoxia-elicited MDR1 expression resulting from HIF-1 activation depends at least in part on signaling via activation of JNK.”
BackgroundRole of hypoxia-inducible factor-1 in transcriptional activation of ceruloplasmin by iron deficiency
Mukhopadhyay, C. K., Mazumder, B., & Fox, P. L. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000636200 · Cited by 274
Cited by
Rohwer, N., & Cramer, T. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.03.001 · Cited by 608
Erin, N., Grahovac, J., Brozovic, A., & Efferth, T. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100715 · Cited by 527
Exercise as adjunct therapy in cancer
Ashcraft, K. A., Warner, A. B., Jones, L. W., & Dewhirst, M. W. (2019) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2018.10.001 · Cited by 148
Hypoxia Inducible Factor Pathway Inhibitors as Anticancer Therapeutics
Burroughs, S. K., Kaluz, S., Wang, D., Wang, K., Van Meir, E. G., & Wang, B. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.17 · Cited by 140
Staab, A., Loeffler, J., Said, H. M., Diehlmann, D., Katzer, A., Beyer, M., Fleischer, M., Schwab, F., Baier, K., Einsele, H., et al. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-213 · Cited by 89
“1α expression by small interfering RNA enhances the susceptibility of oral squamous cell carcinoma cells to chemo- and radiotherapy [23].”
BackgroundRole of enolase-1 in response to hypoxia in breast cancer: exploring the mechanisms of action
GAO, J., ZHAO, R., XUE, Y., NIU, Z., CUI, K., YU, F., ZHANG, B., & LI, S. (2013) · Oncology Reports · doi:10.3892/or.2013.2269 · Cited by 48
Ayrapetov, M. K., Xu, C., Sun, Y., Zhu, K., Parmar, K., D'Andrea, A. D., & Price, B. D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026064 · Cited by 41
Iron Metabolism: State of the Art in Hypoxic Cancer Cell Biology
Liu, S., Cao, X., Wang, D., & Zhu, H. (2022) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2022.109199 · Cited by 31
Metadata
- Authors
- Sasabe, E., Zhou, X., Li, D., Oku, N., Yamamoto, T., & Osaki, T.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2006-10-25
- Volume
- 120
- Issue
- 2
- Pages
- 268-277
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2036022656
- Cited by
- 94
- References
- 9
- FWCI
- 1.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.